Aprea Therapeutics (APRE) Preferred Stock Liabilities (2018 - 2026)

Aprea Therapeutics (APRE) has reported Preferred Stock Liabilities for 7 consecutive years, with $727361.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Preferred Stock Liabilities fell 44.52% year-over-year to $727361.0; the TTM figure through Mar 2026 stood at $727361.0 (down 44.52% YoY), while the FY2025 annual figure was $727361.0, down 44.52% from the prior year.
• Preferred Stock Liabilities held at $727361.0 in Q1 2026 per APRE's latest filing, from $727361.0 in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $68.8 million in Q2 2022 and bottomed at $727361.0 in Q2 2025.
• Historically, Preferred Stock Liabilities has averaged $5.5 million across 5 years, with a median of $1.3 million in 2022.
• On a YoY basis, Preferred Stock Liabilities climbed as much as 0.0% in 2023 and fell as far as 98.09% in 2023.
• Aprea Therapeutics' Preferred Stock Liabilities stood at $1.3 million in 2022, then changed by 0.0% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then plunged by 44.52% to $727361.0 in 2025, then changed by 0.0% to $727361.0 in 2026.
• Business Quant data shows APRE's Preferred Stock Liabilities at $727361.0 in Q1 2026, $727361.0 in Q4 2025, and $727361.0 in Q3 2025.